Future Healthcare Story

Ovarian Cancer Diagnostics Market to Grow at 5.9% of CAGR By 2026

Press release   •   Dec 04, 2019 02:00 EST

The global ​Ovarian Cancer Diagnostics Market size is estimated to grow at CAGR above 5.9% over the forecast time frame 2019-2026 and reach the market value around $1.8 billion by 2026.

The report is titled “Ovarian Cancer Diagnostics Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 – 2026” and it intends to offer a comprehensive overview of the market to its stakeholders.

To keep pace with the increasing demand, the leading organizations are investing in various research and development initiatives. This, coupled with government support, implementation of policies supporting expansion of pharmaceutical and healthcare industries, and accessibility to improved reimbursement policies are supporting the growth of this market.

The report offers a bird’s eye view of the Ovarian Cancer Diagnostics Market, gauging its growth trajectory over the years. It presents insights into key factors boosting the markets, besides the ones restricting its growth. The report also highlights hidden opportunities for the market besides revealing the key restraints. It is therefore intended to help market players determine their growth strategies and make informed decisions pertaining to potential investments.

Download Free Sample Report Pages@ https://www.acumenresearchandconsulting.com/request-sample/1550

The report includes information obtained from various sources from within the industry. Latest statistics from international organizations are considered while compiling this study. In addition to this, opinions from experts are taken to offer refined growth forecasts. Information compiled in the study is derived with primary and secondary research methods. Besides this, industry-leading analytical tools are used examine information received. The report uses price trend analysis, qualitative and quantitative analysis to evaluate prevalent market trends.

Scope of the Report:

The report first uses historic data from different companies. The data collected is used to analyses the growth of industries in the past years. It includes data from the year 2015 to the year 2019. The forecast data provides the reader with an understating of the future of the market. The same data is used to predict the expectation of the companies and how they are expected to evolve in the coming years. The research provides historical as well as estimated data from the year 2019 to 2026. The details in the report give a brief overview of the market by examining its historical data, the current data, and forecast data to understand the growth of the market.

Competitive Landscape

The competition witnessed in the market is soaring. With rising demand for innovation, players are experimenting with various strategies to gain competitive edge and strengthen their foothold in the market. Several companies operating in the industry are looking at expanding their footprint across emerging nations to capitalize on the prevailing opportunities there. The gap in demand and supply of healthcare facilities in underdeveloped countries has resulted in the presence of unmet demand in these countries. These companies are looking at capitalizing on this to emerge at the fore of the global market.

Growth strategies adopted by the companies operating in the market are examined in detail. This is done to study how these strategies influence on this market. Furthermore, the bargaining power of suppliers and buyers. Furthermore, it reveals threat from new entrants and available substitute products.

List of Companies

The report lists down some of the leading companies operating in this market. The market share of the global Ovarian Cancer Diagnostics Market is dominated by companies like GlaxoSmithKline plc; F. Hoffmann-La Roche Ltd.; AstraZeneca plc; Johnson & Johnson Services, Inc.; Siemens Healthcare GmbH; Bio-Rad Technologies Inc.; Thermo Fisher Scientific; and Abbott.

The policies adopted by these companies are studied in detail. Furthermore, the report offers insights into their product portfolio, pricing strategies, strategic collaborations, mergers and acquisitions, among others.

SWOT Analysis is conducted on the companies listed to study their strengths and weaknesses. Furthermore, the analysis offered insights into opportunities and threats present in the market for these companies. A comparative analysis between these companies is intended to highlight the most successful strategies adopted by these companies. Doing so, the report offers recommendations for growth to companies operating in the market. It is thus conducted to help companies, irrespective of their size, access relevant information.

Regional Outlook

The report segments the global Ovarian Cancer Diagnostics Market into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa in terms of region. According to studies, developed economies are likely to offer stability to the market. The higher rate of adoption of latest technologies and the presence of a sophisticated healthcare network will augment growth in the market in North America. In Europe as well the market will gain from favourable government policies.

In the last couple of years, the investment towards expanding healthcare infrastructure has greatly surged in emerging economies of Asia Pacific and Latin America. This, coupled with the rising awareness about various diseases and the treatment available for the same will support growth in emerging countries.

Key Segments

The report segments the market into various categories. The leading segments within each category are identified in the report. Furthermore, it calculates market share that these segments hold. Factors enabling growth in this segments are studied in detail. The report also reveals the factors that may restrain the market growth in these categories.

Market Segmentation

Market, by Diagnosis Type

  • Imaging
    • CT Scan
    • Ultrasound
    • PET Scan
    • MRI Scan
    • Others
  • Biopsy
  • Blood Test
    • BRCA
    • CA125
    • ER & PR
    • HER2
    • CEA
    • KRAS Mutation
    • Others
  • Others

Market, by Cancer Type

  • Germ Cell Tumor
  • Stromal Cell Tumor
  • Epithelial Tumor
  • Others

Market, by End-use

  • Cancer Diagnostic Centers
  • Hospital Laboratories
  • Research Institutes
  • Others

Market Regional Analysis:

Based on the regions, the global Ovarian Cancer Diagnostics Market is segmented into -North America (US and Canada), Europe (UK, Germany, France, Spain and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea and Rest of Asia-Pacific), Latin America (Mexico, Brazil and Rest of Latin America), Middle East & Africa (GCC, South Africa and Rest of MEA)

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Ovarian Cancer Diagnostics
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Ovarian Cancer Diagnostics Market By Diagnosis Type
1.2.2.1. Global Ovarian Cancer Diagnostics Market Revenue and Growth Rate Comparison By Diagnosis Type (2015-2026)
1.2.2.2. Global Ovarian Cancer Diagnostics Market Revenue Share By Diagnosis Type in 2017
1.2.2.3. Imaging
1.2.2.3.1. CT Scan
1.2.2.3.2. Ultrasound
1.2.2.3.3. PET Scan
1.2.2.3.4. MRI Scan
1.2.2.3.5. Others
1.2.2.4. Biopsy
1.2.2.5. Blood Test
1.2.2.5.1. BRCA
1.2.2.5.2. CA125
1.2.2.5.3. ER & PR
1.2.2.5.4. HER2
1.2.2.5.5. CEA
1.2.2.5.6. KRAS Mutation
1.2.2.5.7. Others
1.2.2.6. Others
1.2.3. Ovarian Cancer Diagnostics Market By Cancer Type
1.2.3.1. Global Ovarian Cancer Diagnostics Market Revenue and Growth Rate Comparison By Cancer Type (2015-2026)
1.2.3.2. Germ Cell Tumor
1.2.3.3. Stromal Cell Tumor
1.2.3.4. Epithelial Tumor
1.2.3.5. Others
1.2.4. Ovarian Cancer Diagnostics Market By End Users
1.2.4.1. Global Ovarian Cancer Diagnostics Market Revenue and Growth Rate Comparison By End Users (2015-2026)
1.2.4.2. Cancer Diagnostic Centers
1.2.4.3. Hospital Laboratories
1.2.4.4. Research Institutes
1.2.4.5. Others
1.2.5. Ovarian Cancer Diagnostics Market by Geography
1.2.5.1. Global Ovarian Cancer Diagnostics Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Ovarian Cancer Diagnostics Market Revenue and Growth Rate(2015-2026)
1.2.5.3. Europe Ovarian Cancer Diagnostics Market Revenue and Growth Rate(2015-2026)
1.2.5.4. Asia-Pacific Ovarian Cancer Diagnostics Market Revenue and Growth Rate(2015-2026)
1.2.5.5. Latin America Ovarian Cancer Diagnostics Market Revenue and Growth Rate(2015-2026)
1.2.5.6. Middle East and Africa (MEA) Ovarian Cancer Diagnostics Market Revenue and Growth Rate(2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Hospital Laboratories Production Date of Global Ovarian Cancer Diagnostics Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Ovarian Cancer Diagnostics Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Ovarian Cancer Diagnostics Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Ovarian Cancer Diagnostics Major Manufacturers in 2017

CHAPTER 4. OVARIAN CANCER DIAGNOSTICS MARKET BY DIAGNOSIS TYPE

4.1. Imaging
4.1.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.1.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.1.3. CT Scan
4.1.4. Ultrasound
4.1.5. PET Scan
4.1.6. MRI Scan
4.1.7. Others
4.2. Biopsy
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Blood Test
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3.3. BRCA
4.3.4. CA125
4.3.5. ER & PR
4.3.6. HER2
4.3.7. CEA
4.3.8. KRAS Mutation
4.3.9. Others
4.4. Other
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. OVARIAN CANCER DIAGNOSTICS MARKET BY CANCER TYPE

5.1. Global Ovarian Cancer Diagnostics Revenue by Cancer Type
5.2. Germ Cell Tumor
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Stromal Cell Tumor
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Epithelial Tumor
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Others
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. OVARIAN CANCER DIAGNOSTICS MARKET BY END USERS

6.1. Global Ovarian Cancer Diagnostics Revenue By End Users
6.2. Cancer Diagnostic Centers
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Hospital Laboratories
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Research Institutes
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.5. Others
6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET BY COUNTRY

7.1. North America Ovarian Cancer Diagnostics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Ovarian Cancer Diagnostics Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S.Ovarian Cancer Diagnostics Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
7.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE OVARIAN CANCER DIAGNOSTICS MARKET BY COUNTRY

8.1. Europe Ovarian Cancer Diagnostics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Ovarian Cancer Diagnostics Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET BY COUNTRY

9.1. Asia-Pacific Ovarian Cancer Diagnostics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Ovarian Cancer Diagnostics Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA OVARIAN CANCER DIAGNOSTICS MARKET BY COUNTRY

10.1. Latin America Ovarian Cancer Diagnostics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Ovarian Cancer Diagnostics Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST OVARIAN CANCER DIAGNOSTICS MARKET BY COUNTRY

11.1. Middle East Ovarian Cancer Diagnostics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Ovarian Cancer Diagnostics Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 12. AFRICA OVARIAN CANCER DIAGNOSTICS MARKET BY COUNTRY

12.1. Africa Ovarian Cancer Diagnostics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Ovarian Cancer Diagnostics Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 13. COMPANY PROFILE13.1. GlaxoSmithKline plc
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. F. Hoffmann-La Roche Ltd.
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. AstraZeneca plc
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. Johnson & Johnson Services, Inc.
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. Siemens Healthcare GmbH
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. Bio-Rad Technologies Inc.
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. Thermo Fisher Scientific
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Type Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. Abbott
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Type Portfolio
13.8.5. Key Developments
13.8.6. Strategies
13.9. Others
13.9.1. Company Snapshot
13.9.2. Overview
13.9.3. Financial Overview
13.9.4. Type Portfolio
13.9.5. Key Developments
13.9.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope

The report is readily available and can be dispatched immediately after payment confirmation.

To Purchase this Premium Report@ https://www.acumenresearchandconsulting.com/buy-now/0/1550

Contact Us:

Acumen Research and Consulting

Email: sales@acumenresearchandconsulting.com

Phone: +1 407 915 4157

Latest Healthcare industry news and articles